Dade Behring gets warning letter from FDA
This article was originally published in Clinica
The FDA has accused Dade Behring of failing to take corrective action over problems with preservatives which had resulted in the withdrawal of three loads of Chlamydia test kits. In addition, the FDA says in a warning letter to Dade Behring, the company was slow at processing complaints and problems were found with the sampling plan for reliability testing.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.